Bruker Corporation (NASDAQ:BRKR).
On December 14 the company was downgraded to “Underweight” from “Neutral” with a current price target of $20.00 in a statement from JP Morgan. On December 14, 2016 JP Morgan left the price objective at $20.00 but downgraded the company to Underweight from Neutral.
On November 10, 2016 Leerink Swann began coverage of the stock with a rating of “Market Perform”. Equity analyst BTIG Research initiated coverage on BRKR giving it an initial rating of “Neutral”.
On May 5 the company was rated “Neutral” in a report from BTIG Research a cut from the previous “” rating.
The company is trading down by -0.03 percent from yesterday’s close. Bruker Corporation recently announced a dividend for shareholders paid on Friday the 23rd of June 2017. The dividend was $0.040 per share for the quarter or $0.16 annualized. This dividend amount was represent a yeild of $0.55. The ex-dividend date was Thursday the 1st of June 2017.
Shares are trading at $29.03 which is just over the 50 day moving average of $27.44 and marginally over the 200 day moving average of $24.28. The 50 day moving average moved up $1.59 whereas the 200 day average was up by +19.57%.
Bruker Corporation, launched on February 4, 2000, is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Business’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). The Business’s products address the evolving needs of an array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy and infrared and Raman molecular spectroscopy technologies. It also develops, manufactures and distributes a range of field analytical systems for chemical, biological, radiological, nuclear and explosives (CBRNE) detection. It also develops, manufactures and markets high and low temperature superconducting materials and devices based primarily on metallic low temperature superconductors..
The most current P/E ratio is 30.82 and market capitalization is 4.64B. As of the latest earnings report the EPS was $0.94 and is projected to be $1.10 for the current year with 159,768,000 shares outstanding. Next quarter’s EPS is estimated at $0.27 with next year’s EPS projected to be $1.24.
Investors are feeling more bearish on shares of Bruker Corporation recently as indicated by the increase in short interest. The firm realized a rise in short interest of 12.20% as of May 31, 2017 from the last reporting period. Short shares grew from 2,704,919 to 3,034,785 over that timeframe. Days to cover increased 0.1 to 4.1 and the percentage of shorted shares was 0.02% on May 31.